Making $$ in the Market
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NASDAQ @ IMNP
Listing Requirements for All Companies
Each company must have a minimum of 1,250,000 publicly-traded shares upon listing, excluding those held by officers, directors or any beneficial owners of more then 10% of the company. In addition, the regular bid price at time of listing must be $4, and there must be at least three market makers for the stock. However, a company may qualify under a closing price alternative of $3 or $2 if the company meets varying reequirements. Each listing firm is also required to follow Nasdaq corporate governance rules 4350, 4351 and 4360. Companies must also have at least 450 round lot (100 shares) shareholders, 2,200 total shareholders, or 550 total shareholders with 1.1 million average trading volume over the past 12 months.
In addition to these requirements, companies must meet all of the criteria under at least one of the following standards.
Listing Standard No. 1
The company must have aggregate pre-tax earnings in the prior three years of at least $11 million, in the prior two years at least $2.2 million, and no one year in the prior three years can have a net loss.
Listing Standard No. 2
The company must have a minimum aggregate cash flow of at least $27.5 million for the past three fiscal years, with no negative cash flow in any of those three years. In addition, its average market capitalization over the prior 12 months must be at least $550 million, and revenues in the previous fiscal year must be $110 million, minimum.
Listing Standard No. 3
Companies can be removed from the cash flow requirement of Standard No. 2 if the average market capitalization over the past 12 months is at least $850 million, and revenues over the prior fiscal year are at least $90 million.
Investor 100
Strong Buy @ IMNP
Analyst Firms Making Recommendations
FBR CAP MARKETS
ROTH CAPITAL PA
ZACKS SMALL CAP
Read more: http://www.nasdaq.com/symbol/imnp/recommendations#ixzz4CcZNHiuh
Intertesting @ IMNP
This opportunity could be interesting ...hmmm
License Option Agreement
https://www.sec.gov/Archives/edgar/data/1208261/000114420416102729/v439810_ex10-3.htm
This Agreement made this day of May 15, 2016 by and between Immune Pharmaceuticals Inc. (“Immune”) with a principal place of business at 430 East 29th Street, Suite 940, New York, NY 10016 and Novel Pain Therapeutics LLC (“NPT”), a newly formed limited liability company with an office at 52 East End Avenue #12A New York, NY 10028
Whereas Immune has intellectual property rights pertaining to its product AmiKet™ and Amiket™ Nano, which are proprietary combinations of amitriptyline and ketamine in topical formulations to treat neuropathic pain, and related product formulations, technical information, clinical data, know-how, patents and patent applications, and trademarks (“Product”).
License Option
1.1 Immune hereby grants NPT an exclusive option to negotiate an exclusive worldwide royalty-bearing license (the “License”), including the right to grant sublicenses, to make, use, sell, offer for sale and import products under all Immune’s right, title and interest in Product. Such right shall apply during the “Term” beginning from the day of signing of this Agreement by both Parties and extending for 60 days unless otherwise extended by the Parties in writing.
1.2 Immune hereby represents and warrants that Immune has good title to all rights pertaining to the Product, free and clear of all liens, encumbrances and adverse claims, subject to the terms of any license agreements pertaining thereto, which Immune represents and warrants are in full force and effect and as to which there are no breaches or defaults thereunder.
1.3 During the Term of the Agreement, beginning on May 15, 2016 and extending for 60 days unless otherwise extended in writing by the Parties:
1.3.1 Immune shall continue to conduct ongoing Product research and development;
.
1.3.2 Immune shall not enter into any other contract that would affect NPT potential rights to the Product or take any action that would interfere in any material respect with Immune’s ability to perform any of its obligations hereunder;
1.3.3 NPT shall diligently pursue obtaining equity funding to be used to conduct initial Product development and commercialization as described below; and
1.3.4 The Parties shall negotiate in good faith a license agreement with material terms as outlined in Exhibit A (the “License Agreement”). In the event the Parties have not executed a License Agreement by the end of the Option Period, the Agreement shall terminate and the Parties shall have no further obligation to each other in connection with the negotiation and execution of a License Agreement.
1.3.5 Immune shall provide NPT with full access to all material information, documents and data pertaining to the Product, including without limitation copies of all license agreements, patent applications and submissions to and responses from each patent office, trademark registrations, clinical data and reports, submissions to and responses from each regulatory authority, including the US Food and Drug Administration, and market studies and surveys, research reports, and a schedule of Product costs incurred,
1.4 In consideration for Immune’s grant of the option to NPT, NPT shall within 15 days prior to the expiration of the Option Period (the “Escrow Due Date”) establish a $500,000 escrow account to be held during the Term, unless terminated prior to the Escrow Due Date by NPT. The escrow balance shall be paid to NPT should the Parties fail to execute a License Agreement during the Term or to Immune at execution of the License Agreement as provided in the Licens
Hot Stock under Consideration: Immune Pharmaceuticals, Inc. (NASDAQ:IMNP)
http://www.newsoracle.com/2016/06/22/hot-stock-under-consideration-immune-pharmaceuticals-inc-nasdaqimnp/
The Company gained 35.22% and finished at $0.54. The daily volume was measured at 9.55 million shares. The 52-week high of the share price is $2.06 and the 52-week low is $0.2. The company has a market cap of $21.4 million. Its latest closing price has a distance of 43.07% from SMA20 and is 45.25 up than SMA50.
IMNP is currently showing 53.49 million shares outstanding as compared with the 32.08 million total shares float.
The Stock has its Beta Value of 1.36 and ATR (Average True Range) of 0.07. The Weekly and Monthly Volatility of the stock are 16.44% and 21.97% respectively. The weekly performance of the company stands at -18.35 percent while it’s 1-month and 3-month returns are 53.88 percent and -19.98 percent.
By looking at Immune Pharmaceuticals, Inc. (IMNP) YTD (year to date) performance, the stock shows Negative value of -45.19%. If the YTD value is Negative, it means that the stock is trading poorly. If the YTD value is Positive, this means the stock is appreciating.
The High price target of the company’s Share is at $3 based on the calculations and analysis of 2 brokers. According to the analysts, the company has the Low Price target of $1 whereas, the Mean Target is estimated by the brokers is $2.
For an overview on Recommendation Trends, 1 Analysts assigned the stock as Strong Buy. 2 said it’s a Buy, 0 assigned Hold rating where 0 stated the stock as Underperform and 0 marked the stock as Sell.
While Looking at the Earnings Estimates of the company, The Average Earnings Estimate for the Current Fiscal quarter is measured as -$0.13 by 2 analysts. They are also projecting the Low EPS estimate as -$0.14 as compared to the Higher EPS estimate of -$0.12.
TGIF @ IMNP
With the Dow down 400Pts today presented some buying opportunities including IMNP. Took advantage of todays dip and backed up the truck for what I think are cheap shares at these prices.
Solid News: June 20,22016
New Data shows that Ceplene® Enhances Response to anti PD-1 and anti-PD-L1 Immune Checkpoint Inhibitors in Lymphoma and Solid Tumor Models
https://finance.yahoo.com/news/data-shows-ceplene-enhances-response-213000513.html
CEO D.Tiper has bought over 187K shares in 2016 well above todays prices...57,59,62,81...
http://openinsider.com/search?q=imnp
Investor 100
FDA Approval @ OPK
Pleased to be a shareholder!
https://finance.yahoo.com/news/fda-approves-drug-application-rayaldee-060000066.html
FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease
Approval Based Upon Two Randomized, Double Blind, Placebo Controlled Trials and an Open Label Extension Study
There are Approximately 9 Million Patients in the U.S. with SHPT, Stage 3 or 4 CKD and Vitamin D Insufficiency; Large Potential U.S. Market
U.S. Launch Planned for 2H 2016
OPKO Health, Inc. (OPK) announced that the U.S. Food and Drug Administration (FDA) has approved RAYALDEE® (calcifediol) extended release capsules for the treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. RAYALDEE is a patented extended release product containing 30 mcg of a prohormone called calcifediol (25-hydroxyvitamin D3).
“FDA’s approval of RAYALDEE represents an important milestone for OPKO,” noted Dr. Phillip Frost, CEO and Chairman of OPKO. "RAYALDEE is the first product to receive FDA approval for this important indication and is one of OPKO’s many pharmaceutical products being developed for significant medical problems which will benefit from new treatment options.”
Results from two 26 week placebo controlled, double blind phase 3 trials demonstrated that a larger proportion of stage 3 or 4 CKD patients with SHPT and vitamin D insufficiency achieved ≥30% reductions in plasma intact parathyroid hormone (iPTH) when treated with RAYALDEE than with placebo. Vitamin D insufficiency was corrected in more than 80% of the patients receiving RAYALDEE compared with less than 7% of subjects receiving placebo. Mean serum calcium and phosphorus levels increased by 0.1 mg/dL during RAYALDEE treatment compared to placebo treatment, but these changes were deemed clinically irrelevant. No differences in RAYALDEE’s efficacy or safety were observed between patients with stage 3 CKD or stage 4 CKD.
“RAYALDEE fills a large void in the current treatment options for SHPT in predialysis patients,” commented Dr. Charles W. Bishop, CEO of OPKO’s Renal Division. “The current standard of care is high dose vitamin D supplementation, an approach for treating SHPT that is neither FDA approved nor demonstrated to be safe and effective in this population. SHPT is a progressive disease that becomes increasingly debilitating and difficult to treat, necessitating timely and effective treatment.”
“RAYALDEE is an important new option for treating SHPT in patients with stage 3 or 4 CKD and vitamin D insufficiency,” stated Kevin J. Martin, Director of Research, Division of Nephrology at Saint Louis University School of Medicine. “The great majority of SHPT cases in this patient population are associated with vitamin D insufficiency, a problem that RAYALDEE can correct.”
About RAYALDEE
RAYALDEE (calcifediol) extended release capsules are approved by the U.S. Food and Drug Administration (FDA) for the treatment of SHPT in adult patients with stage 3 or 4 CKD and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. RAYALDEE has a patented formulation designed to raise serum total 25-hydroxyvitamin D (prohormone) concentrations to targeted levels (at least 30 ng/mL) and to reduce elevated iPTH. OPKO expects to launch RAYALDEE in the U.S. through its dedicated renal sales force in the second half of 2016. RAYALDEE is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis. The full prescribing information for RAYALDEE will be available at www.opkorenal.com.
Potential side effects of RAYALDEE include hypercalcemia (elevated serum calcium), which can also lead to digitalis toxicity, and adynamic bone disease with subsequent increased risk of fractures if intact PTH levels are suppressed by RAYALDEE to abnormally low levels. Severe hypercalcemia may require emergency attention; symptoms of hypercalcemia may include feeling tired, difficulty thinking clearly, loss of appetite, nausea, vomiting, constipation, increased thirst, increased urination, and weight loss. Digitalis toxicity can be potentiated by hypercalcemia of any cause. Excessive administration of RAYALDEE can cause hypercalciuria, hypercalcemia, hyperphosphatemia, or oversuppression of intact PTH. Common symptoms of vitamin D overdosage may include constipation, decreased appetite, dehydration, fatigue, irritability, muscle weakness, or vomiting. Patients concomitantly taking cytochrome P450 inhibitors, thiazides, cholestyramine, phenobarbital or other anticonvulsants may require dose adjustments and more frequent monitoring.
The most common adverse reactions in clinical trials (≥3% and more frequent than placebo) were anemia, nasopharyngitis, increased blood creatinine, dyspnea, cough, congestive heart failure and constipation.
About Chronic Kidney Disease
CKD is a condition characterized by a progressive decline in kidney function. The kidney is normally responsible for excreting waste and excess water from the body, and for regulating various hormones. CKD is classified in five stages — mild (stage 1) to severe (stage 5) disease — as measured by the kidney's glomerular filtration rate. According to the National Kidney Foundation, CKD afflicts over 26 million people in the U.S., including more than 20 million patients with moderate (stages 3 or 4) and severe (stage 5) forms of CKD. In stage 5 CKD, kidney function is minimal to absent and patients require regular dialysis or a kidney transplant for survival. Rayaldee is only indicated for treating SHPT in patients with stage 3 or stage 4 CKD.
About Secondary Hyperparathyroidism (SHPT)
SHPT is a condition commonly associated with CKD in which the parathyroid glands secrete excessive amounts of parathyroid hormone (PTH). SHPT arises as a result of vitamin D insufficiency or impaired kidney function that prevents sufficient production of vitamin D hormone to properly regulate calcium and phosphorus metabolism, and PTH secretion. Prolonged elevation of blood PTH causes excessive calcium and phosphorus to be released from bone, leading to elevated serum calcium and phosphorus, softening of the bones (osteomalacia) and calcification of vascular and renal tissues. SHPT affects 40-60% of patients with moderate CKD and approximately 90% of patients with severe CKD.
About Vitamin D Insufficiency
Vitamin D insufficiency is a condition in which the body has low vitamin D stores, characterized by inadequate blood levels of vitamin D prohormone, known as 25D. An estimated 70-90% of CKD patients have vitamin D insufficiency, which can lead to SHPT and resultant debilitating bone diseases. Vitamin D insufficiency has been associated with increased mortality in CKD.
About OPKO Health, Inc.
OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation’s third largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros®1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency, and VARUBI™ for chemotherapy induced nausea and vomiting (oral formulation launched by partner Tesaro and IV formulation PDUFA date: January 2017). Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), and a long acting Factor VIIa drug for hemophilia (Phase 2a). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at www.opko.com.
Investor 100
Correction @ IMNP
Today's activity presented more opportunity to buy the dips which is what I did given these levels and think this stock presents some strong upward mobilty given recent news.
GLTA
Investor 100
Daniel Teper (CEO) @ IMNP
Daniel has to be very happy with todays news given his buying spree the past 12 months!
http://openinsider.com/search?q=imnp
Investor 100
AH @ IMNP
Postive news has some strong AF going on with over 60K shares traded at .55 or 37% what looked like a greart day to buy on the dip which is what many did including myself!
Tomorrow should be very positive as we move much higher (IMHO).
Investor 100
New Data shows that Ceplene® Enhances Response to anti PD-1 and anti-PD-L1 Immune Checkpoint Inhibitors in Lymphoma and Solid Tumor Models
https://finance.yahoo.com/news/data-shows-ceplene-enhances-response-213000513.html
New Data Presented at the Conference "Regulatory Myeloid Suppressor Cells: From Basic Discovery to Therapeutic Application" Expands Knowledge of Ceplene® Mechanism of Action and Identifies Potential New Indications for Solid Tumors and Lymphoma
NEW YORK, June 20, 2016 /PRNewswire/ -- Immune Pharmaceuticals (IMNP),("Immune"), a clinical stage biopharmaceutical company announced that scientists from Gothenburg University, Sweden reported that new mechanistic and tumor growth inhibition data with Ceplene ® (histamine dihydrochloride) in combination with immune checkpoint inhibitors targeting PD-1 and PD-L1 in Acute Myeloid Leukemia (AML), lymphoma and breast cancer models, has been presented in Poster Session 2 on Saturday, June 18th, at 1:00 pm at the conference on "Regulatory Myeloid Suppressor Cells: From Basic Discovery to Therapeutic Application" held at the Wistar Institute in Philadelphia, PA.
Prof. Kristoffer Hellstrand, laboratory chief at the Sahlgrenska Cancer Center of Gothenburg University and Ceplene ® inventor stated: "These in vivo results imply that Ceplene ® suppresses tumor growth by inhibiting NOX-2, a type of immune check point. The data also suggest that Ceplene ® significantly improves the anti-tumor efficacy of immune checkpoint inhibitors targeting PD-1 and PDL-1 in cancer forming the basis for the clinical development of Ceplene ® and other immune checkpoint inhibitors in lymphomas and solid tumors."
Ceplene ®, in combination with low-dose SC Proleukin® (Interleukin-2 (IL-2)), has been approved in over 30 countries in Europe and Israel for the treatment of AML for maintenance of remission and prevention of disease relapse, an indication for which there are currently no other approved therapies.
In the first presentation, H. Grauers Wiktorin, et al, demonstrated decreased accumulation of myeloid-derived suppressor cells (MDSC) in the tumors accompanied by decreased growth in breast and lymphoma murine cancel models. MDSC harvested from Ceplene- treated animals demonstrated significantly less NOX2-derived Reactive Oxygen Species (ROS) and consequent loss of ability to inhibit T-cell proliferation as compared to MDSC from non-treated animals. Moreover, when combined in these models with checkpoint inhibitors targeting PD-1 and PDL-1, growth inhibition was markedly enhanced compared to either Ceplene ® or the checkpoint inhibitors alone.
In the second presentation, R. Kiffin, et al. demonstrated that Ceplene®-induced downregulation of NADPH Oxidase (NOX2) resulted in increased differentiation and decreased growth of human myelomonoblastic PLB-985 (PLB) xenografts in immunodeficient mice. This provides further mechanistic evidence to explain the striking efficacy of Ceplene ® in combination with low dose IL-2 observed clinically in the myelomonocytic M4 and M5 AML subtypes in both Phase III and Phase IV clinical trials. These results suggest that Ceplene®, in addition to its previously documented role as an innate immune check point inhibitor, acts also as a maturation agent in AML decreasing the tumor's ability to proliferate.
About Immune Pharmaceuticals Inc.:
Immune Pharmaceuticals Inc. (IMNP) applies a personalized approach to treating and developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune's lead product candidate, bertilimumab, is in Phase II clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan autoimmune dermatological condition. Other indications being considered for development include severe atopic dermatitis, Crohn's disease, severe asthma and NASH (an inflammatory liver disease). Immune recently expanded its portfolio in immuno-dermatology with topical nano-formulated cyclosporine-A for the treatment of psoriasis and atopic dermatitis. Immune's oncology pipeline includes Ceplene® approved in combination with lose dose SC IL-2 in Europe and Israel for maintenance remission in AML, Azixa and crolibulin, Phase II-ready vascular disrupting agents, and novel technology platforms; bispecific antibodies and targeted nanotherapeutics, NanomAbs. Immune's additional pipeline includes AmiKet Nano™, a late clinical stage drug candidate for the treatment of neuropathic pain. For more information, visit Immune's website at www.immunepharmaceuticals.com, the content of which is not a part of this press release.
Investor 100
Immune Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016
https://finance.yahoo.com/news/immune-pharmaceuticals-present-jmp-securities-120600041.html
Dr. Daniel Teper, CEO of Immune, will provide an overview of the Company's business and 2016-17 expected milestones, including updates on:
- The advancement of the two Phase 2 clinical trials in bullous pemphigoid, and orphan auto-immune skin disease, and in ulcerative colitis with bertilimumab, a fully human monoclonal antibody targeting eotaxin-1, a key regulator of immuno-inflammation and,
- The company's immuno-oncology pipeline with a focus on new data and strategy for Ceplene®, a type of immune check-point inhibitor in development in combination with low dose SC Proleukin® for the maintenance of remission in patients with Acute Myeloid Leukemia.
The presentation will be webcast and available on our website (www.immunepharma.com) after the conference.
Investor 100
AH @ IMNP
PPS:.57 trading over 19K shares...onward and upward!
Investor 100
Building A Better World Through Medicine
http://www.hadassah-med.com/news.aspx
http://www.hadassah-med.com/about.aspx
Hadasit collaborates with leading international companies and research facilities, such as Johnson & Johnson, Harvard Medical School, Teva and others, as well as incubators and venture capital groups such as BiolineRx, Clal Biotechnologies and Pontifax. Hadasit investment and partner companies include Alcobra, Oramed, Kahr Medical, Imuron and others.
Investor 100
IMUC @ Stockcharts
This stock back on watchlist and will re-enter a position below.25
ImmunoCellular Therapeutics Treats First Patient in ICT-107 Phase 3 Registrational Trial in Newly Diagnosed Glioblastoma
https://finance.yahoo.com/news/immunocellular-therapeutics-treats-first-patient-100000860.html
ImmunoCellular has reached agreement with the US FDA on a Special Protocol Assessment (SPA) relative to the primary and secondary endpoints as well as the statistical plan for the phase 3 trial. ImmunoCellular has also been honored with a $19.9 million award from the governing Board of the California Institute for Regenerative Medicine (CIRM),
Investor 100
Closing Bell @ IMNP
PPS:.523 (+45.28%) over 6.2M shares traded...solid day!
Investor 100
Update @ IMNP
PPS:.48 (+33%) 5.8M shares traded..
Investor 100
Update @ IMNP
.5553 (+54%) 4.9M shares traded...price is cheap based upon a target price of $3.50
Immune Pharmaceuticals Inc
Given the fact the CEO has paid higher prices and this target number of $3.50...buying the dips again!
http://openinsider.com/search?q=imnp
http://www.smarteranalyst.com/2016/06/03/biotech-beat-fbr-analysts-weigh-galena-biopharma-inc-gale-peregrine-pharmaceuticals-pphm-immune-pharmaceuticals-inc-imnp/
Analyst Vernon Bernardino was out pounding the table on Immune Pharmaceuticals Inc (NASDAQ:IMNP), reiterating an Outperform rating and price target of $3.00, which implies an upside of 747.5% from current levels.
Bernardino wrote, “We think IMNP is currently undervalued when considering the collective value of its clinical-stage assets. Following Jazz Pharmaceuticals’ (JAZZ) recent announcement of its $1.5B acquisition of Celator Pharmaceuticals (CPXX) for Vyxeos, the latter’s Phase III stage product candidate for acute myeloid leukemia (AML), we particularly think Ceplene, an IMNP asset already approved in the EU and Israel as a treatment for maintenance of complete response (CR) in patients with AML, alone is undervalued.”
“We believe that Ceplene’s value has been overlooked, and we regard finalizing the design of a U.S. pivotal trial with the FDA as a catalyst that could be positive for IMNP stock later this year,” the analyst added
As of this writing, all the 3 analysts polled by TipRanks rate Immune Pharmaceuticals stock a Buy. With a return potential of 889%, the stock’s consensus target price stands at $3.50.
Investor 100
Update @ IMNP
.5107 +41% 2.7M shares traded...bought more shares!
Investor 100
Immune Pharmaceuticals and Hadasit File a Joint Patent on the Oral Use of Anti-Eotaxin Monoclonal Antibodies, Including Bertilimumab, for the Treatment of GI and Liver Diseases
https://finance.yahoo.com/news/immune-pharmaceuticals-hadasit-file-joint-235600618.html
June 7, 2016 /PRNewswire/ -- Immune Pharmaceuticals Inc. ("Immune"), a biopharmaceutical company focused on the development of antibody-based therapeutics for the treatment of inflammatory diseases and cancer, and Hadasit, the Technology Transfer company of The Hadassah Medical Organization in Jerusalem, Israel, announced today that they together filed a provisional patent on the oral use of anti-eotaxin monoclonal antibodies, including Immune's bertilimumab, for the treatment of inflammatory gastro-intestinal (GI) and liver diseases. Immune signed a licensing agreement with Hadasit in conjunction with the provisional patent filing.
"Oral administration of a non-absorbable mouse anti-eotaxin-1 antibody showed biological activity in the gut, and exerted a systemic immuno-modulatory effect to alleviate immune-mediated hepatitis in an animal model. The data suggests that testing for eotaxin-1 serum levels, and using oral bertilimumab, a fully human monoclonal antibody, may enable the identification and treatment of patients with high-eotaxin-1-associated NASH," said Professor Yaron Ilan, Professor of Medicine, Gastro-Enterology and Liver Units and Director, Department of Medicine at Hebrew University's Hadassah Hospital in Jerusalem, Israel, who conducted the research supporting the provisional patent application.
Immune is currently conducting a double blind placebo controlled phase IIA clinical trial in Ulcerative Colitis, with parenteral bertilimumab. Immune is currently collaborating with Professor Arun Sanyal, former President of the American Liver Association, and Professor of Medicine at Virginia Commonwealth University (VCU) Medical Center to obtain additional insights on the potential role of eotaxin in NASH. Phase II clinical trials in patients with NASH are planned to follow these collaborative studies.
Eotaxin-1, a specific chemokine, plays a role in both innate and adaptive immune responses and modulates the cross-talk between key cells involved in inflammation. Bertilimumab is a first-in-class monoclonal antibody that blocks eotaxin-1, is designed for personalized therapy in inflammatory conditions mediated by high eotaxin-1 levels, among which are Crohn's Disease and Ulcerative Colitis, NASH, and primary sclerosing cholangitis (PSC). Alleviation of insulin resistance is also associated with decreased eotaxin-1.
"Personalized therapies may help provide an optimized safety-to-efficacy ratio by selecting patients with higher response rates based on specific biomarkers," adds Professor Ilan.
Immune Pharmaceuticals Inc
Given the fact the CEO has paid higher prices and this target number of $3.50...buying the dips again!
http://openinsider.com/search?q=imnp
http://www.smarteranalyst.com/2016/06/03/biotech-beat-fbr-analysts-weigh-galena-biopharma-inc-gale-peregrine-pharmaceuticals-pphm-immune-pharmaceuticals-inc-imnp/
Analyst Vernon Bernardino was out pounding the table on Immune Pharmaceuticals Inc (NASDAQ:IMNP), reiterating an Outperform rating and price target of $3.00, which implies an upside of 747.5% from current levels.
Bernardino wrote, “We think IMNP is currently undervalued when considering the collective value of its clinical-stage assets. Following Jazz Pharmaceuticals’ (JAZZ) recent announcement of its $1.5B acquisition of Celator Pharmaceuticals (CPXX) for Vyxeos, the latter’s Phase III stage product candidate for acute myeloid leukemia (AML), we particularly think Ceplene, an IMNP asset already approved in the EU and Israel as a treatment for maintenance of complete response (CR) in patients with AML, alone is undervalued.”
“We believe that Ceplene’s value has been overlooked, and we regard finalizing the design of a U.S. pivotal trial with the FDA as a catalyst that could be positive for IMNP stock later this year,” the analyst added
As of this writing, all the 3 analysts polled by TipRanks rate Immune Pharmaceuticals stock a Buy. With a return potential of 889%, the stock’s consensus target price stands at $3.50.
Investor 100
Form 4 @ IMNP
D.Teper piling on more shares 180,000 / .40 ( stock options).
http://ih.advfn.com/p.php?pid=nmona&article=71653358
Investor 100
(April 2016)New Biomarker Data To Be Presented at AACR Helps Predict Overall Survival in Patients with Acute Myeloid Leukemia (AML) Treated with Ceplene® and Low-dose IL-2 Immunotherapy, Including Those Over 60 Years of Age
Apr 19, 2016
NEW YORK, April 19, 2016 /PRNewswire/ -- Scientists from Gothenburg University, Sweden will report data today at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, LA, on an immune mechanism-based biomarker to predict the potential efficacy of treatment with Ceplene® in the difficult-to-treat above 60 year old population with Acute Myeloid Leukemia (AML). Ceplene, in combination with low-dose Interleukin-2 (IL-2), is currently approved but not actively marketed in over 30 countries in Europe and Israel for the treatment of AML for maintenance of remission and prevention of disease relapse, an indication for which there are no other approved therapies.
Since the previous Ceplene/IL-2 phase III trial, which demonstrated an almost 50% improvement in 2 year leukemia free survival (LFS) in the overall population treated with Ceplene immunotherapy, a great deal has been learned about the biology of Ceplene® based immune-regulation. In AML, histamine H2 Receptors (H2R) are predominantly expressed on FAB subtypes with monocytic differentiation, namely M4 and M5. In these subtypes, the binding of histamine to the H2R results in down-regulation of NOX2 with resultant decreased production of Reactive Oxygen Species (ROS) and subsequent protection of deleterious immune cells from deactivation and death. When combined with low dose IL-2, Ceplene allows for the activation of the T and Natural Killer (NK) cells toward a tumor killing effect.
In the Phase IV international study, which will be presented at the AACR Annual Meeting today, a reduction in the frequency of CD8+ T effector memory (TEM) cells during the first cycle of HDC/IL-2 prognosticated LFS (HR 0.25, P=0.001) and OS (HR 0.24, P=0.009). Similarly, induction of T effector cells (Teff) during cycle 1 impacted favorably on outcome (P=0.048 for OS). Patients with a concomitant reduction of TEM cells and induction of Teff cells during immunotherapy showed an even more favorable outcome in terms of LFS (HR 0.19, P=0.001) and OS (HR 0.13, P=0.008). Thus, the altered distribution of cytotoxic T cells during treatment with HDC/IL-2 significantly prognosticated LFS and OS especially within the group of elderly patients (above 60 years of age), providing a potential personalized approach for treating the more therapy-resistant older AML patient population, in addition to selection of the population most likely to benefit by FAB subtype.
Miri Ben-Ami, MD, President, Immune Oncology Pharmaceuticals Inc. stated, "We believe that the new data may allow a personalized approach to selection of patients who are most likely to benefit from Ceplene/IL-2 treatment in AML, in particular the older patient population who have demonstrated almost 100% survival when positive for the T-cell transition biomarkers." Dr. Ben-Ami continued, "In addition, current research is revealing the potential synergy between immune checkpoint inhibitors and Ceplene, which could open the possibility of additional therapeutic indications for this combination."
About Immune Pharmaceuticals Inc.:
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) applies a personalized approach to treating and developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune's lead product candidate, bertilimumab, is in Phase II clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan autoimmune dermatological condition. Other indications being considered for development include atopic dermatitis, Crohn's disease, severe asthma and NASH (an inflammatory liver disease). Immune recently expanded its portfolio in immuno-dermatology with topical nano-formulated cyclosporine-A for the treatment of psoriasis and atopic dermatitis. Immune's oncology pipeline includes Ceplene/IL-2 approved in Europe and Israel for maintenance remission in AML, Azixa and crolibulin, Phase II-ready vascular disrupting agents, and novel technology platforms; bispecific antibodies and targeted nanotherapeutics, NanomAbs. Immune's additional pipeline includes AmiKet Nano™, a late clinical stage drug candidate for the treatment of neuropathic pain. For more information, visit Immune's website at www.immunepharmaceuticals.com, the content of which is not a part of this press release.
Forward-Looking Statements
This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal" or the negative of those words or other comparable words to be uncertain and forward-looking. Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include, but not limited to: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for bertilimumab or AmiKet will not be successful; the risk that bertilimumab, AmiKet or compounds arising from our NanomAbs program will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet on attractive terms, on a timely basis or at all; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K and 10-Q and our annual report on Form 10-K for the year ended December 31, 2015 and other filings with the U.S. You are urged to carefully review and consider the disclosures found in our filings, which are available at www.sec.gov or at www.immunepharmaceuticals.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors. We expressly disclaim any obligation to publicly update any forward looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.
SOURCE Immune Pharmaceuticals Inc.
For further information: For further information: Danielle Shapira, Manager, Strategic Planning, Immune Pharmaceuticals Inc., 646.440.9327, danielle.shapira@immunepharma.com
print email rss
AddThis Sharing Buttons
Share to FacebookShare to Google+Share to TwitterShare to FavoritesShare to LinkedInMore AddThis Share options
© Copyright 2014
Power Hour @ IMNP
.395 (+19%) over 5.2M shares traded...busy two days of trading!
Investor 100
IMNP>>>.39 (+18% 5M shares traded
Investor 100
New Financing Agreement Announced (July 2015)- CEO D. Teper
Interview with Yaron Ilan
IMNP@ Stockcharts
Monster run this week from the low 20's to the 40's!
Like RSI..MACD and MFI...follow the money as well as the CEO buying his stockpile in Dec/Jan at much higher prices!
http://openinsider.com/search?q=imnp
Investor 100
IMNP>>>.42 (+27%) over 1M shares traded...
Investor 100
IMNP Recap: Closed .332 (+58.1%) 2.7M shares traded...CEO Teper bought a bunch in Dec/Jan at much higher prices...the train has not yet left the station..should be interesting in the days ahead..buckle up for the ride!
Investor 100
IMNP Update....3299 (+57%) almost 2.5 M shares traded..something abounds here...hmmm
Investor 100
IMNP Update: +33% gainer, .28 almost 2M shares traded!
Investor 100
IMUC @ Stockcharts
Looking forward to this update!
Major Shareholders:https://finance.yahoo.com/q/mh?s=IMUC+Major+Holders
Investor 100
Marcum MicroCap Conference on June 2, 2016
https://finance.yahoo.com/news/immunocellular-therapeutics-present-marcum-microcap-100000122.html
LOS ANGELES, May 23, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the Marcum MicroCap Conference on Thursday, June 2, 2016 at 2:00 pm ET at the Grand Hyatt hotel, New York, New York.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The phase 3 registrational trial of lead product candidate, ICT-107, a patient-specific, dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells, is open for patient screening. ImmunoCellular's pipeline also includes: ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. To learn more about ImmunoCellular, please visit www.imuc.com.
Investor 100
IMNP Recap R & D
Alot going on here with R&D and of late we see alot of acquisitions....CEO bought a ton of stock in early 2016could we have one here....hmmm
https://finance.yahoo.com/news/immune-pharmaceuticals-provides-business-r-113000807.html
CEO keeps buying shares!
http://openinsider.com/search?q=imnp
NEW YORK, May 16, 2016 /PRNewswire/ -- Immune Pharmaceuticals Inc. (IMNP) ("Immune" or the "Company") announced financial results for the first quarter ended March 31, 2016.
Business and Research & Development ("R&D") Update
Immune continues to pursue its strategy to unlock the value of its diversified pipeline through the development, financing and strategic partnering of specifically focused asset groups:
Immuno-inflammation focus on gastro-enterology and dermatology through a pipeline comprised of two assets: bertilimumab, currently in two phase II clinical trials in ulcerative colitis and bullous pemphigoid with a third phase II planned in severe atopic dermatitis, and topical nano-formulated cyclosporine for the treatment of atopic dermatitis and psoriasis.
Immuno-oncology subsidiary that includes three mid-to-late stage clinical assets (Ceplene®, Azixa®, Crolibulin®) as well as novel platforms: bispecific antibodies and NanomAbs ®, antibody nanoparticle conjugates.
The licensing of AmiKet® and AmiKet® Nano for the treatment of peripheral neuropathic pain to a newly-created pain specialty pharma company:
Immune executed an exclusive 60-day option with Novel Pain Therapeutics ("NPT") to enter into a worldwide license agreement for AmiKet and AmiKet Nano for the treatment of peripheral neuropathic pain. Upon execution of the license agreement pursuant to agreed material terms in the option, NPT will assume all research and development costs and Immune will be eligible to receive up to $160 million, comprised of an upfront fee of at least $15 million in the form of equity in NPT, up to $25 million in development milestones, and up to $120 million in commercial milestones, as well as product sales royalties. Immune will also be eligible to receive 25% and up to 50% of sublicense fees received by NPT.
Immune continues to execute its R&D plan with progress for all its key assets:
Continued enrollment into the two Phase II clinical trials with bertilimumab.
Publication in Oncotarget and presentation at the American Academy of Cancer Research (AACR) meeting of European phase IV studies highlighting predictive bio-markers of overall survival in maintenance of first remission in patients with acute myeloid leukemia. Immune intends to submit to the Food and Drug Administration a plan for a pivotal overall survival study with Ceplene® in combination with low dose IL-2 (Proleukin®).
On-going development and testing of new bi-specific antibodies targeting PD-1 and OX40 (two immune check points) and PDL-1 and BCMA (an immune check point and a tumor marker of multiple myeloma).
On-going development of topical nano-formulated cyclosporine toward an investigational new drug application and initiation of 505(b) 2 clinical development.
"We are structuring the Company strategically to ensure long term comprehensive financing of our product pipeline and enable focused execution" said Dr. Daniel Teper, CEO of Immune Pharmaceuticals Inc. "We continue to progress in our clinical trials with bertilimumab as we increase patient enrollment and we are on track to achieve our operational and financial objectives for 2016."
Investor 100
Immune Pharmaceuticals Provides Business and R&D Update and Announces First Quarter 2016 Financial Results
https://finance.yahoo.com/news/immune-pharmaceuticals-provides-business-r-113000807.html
NEW YORK, May 16, 2016 /PRNewswire/ -- Immune Pharmaceuticals Inc. (IMNP) ("Immune" or the "Company") announced financial results for the first quarter ended March 31, 2016.
Business and Research & Development ("R&D") Update
Immune continues to pursue its strategy to unlock the value of its diversified pipeline through the development, financing and strategic partnering of specifically focused asset groups:
Immuno-inflammation focus on gastro-enterology and dermatology through a pipeline comprised of two assets: bertilimumab, currently in two phase II clinical trials in ulcerative colitis and bullous pemphigoid with a third phase II planned in severe atopic dermatitis, and topical nano-formulated cyclosporine for the treatment of atopic dermatitis and psoriasis.
Immuno-oncology subsidiary that includes three mid-to-late stage clinical assets (Ceplene®, Azixa®, Crolibulin®) as well as novel platforms: bispecific antibodies and NanomAbs ®, antibody nanoparticle conjugates.
The licensing of AmiKet® and AmiKet® Nano for the treatment of peripheral neuropathic pain to a newly-created pain specialty pharma company:
Immune executed an exclusive 60-day option with Novel Pain Therapeutics ("NPT") to enter into a worldwide license agreement for AmiKet and AmiKet Nano for the treatment of peripheral neuropathic pain. Upon execution of the license agreement pursuant to agreed material terms in the option, NPT will assume all research and development costs and Immune will be eligible to receive up to $160 million, comprised of an upfront fee of at least $15 million in the form of equity in NPT, up to $25 million in development milestones, and up to $120 million in commercial milestones, as well as product sales royalties. Immune will also be eligible to receive 25% and up to 50% of sublicense fees received by NPT.
Immune continues to execute its R&D plan with progress for all its key assets:
Continued enrollment into the two Phase II clinical trials with bertilimumab.
Publication in Oncotarget and presentation at the American Academy of Cancer Research (AACR) meeting of European phase IV studies highlighting predictive bio-markers of overall survival in maintenance of first remission in patients with acute myeloid leukemia. Immune intends to submit to the Food and Drug Administration a plan for a pivotal overall survival study with Ceplene® in combination with low dose IL-2 (Proleukin®).
On-going development and testing of new bi-specific antibodies targeting PD-1 and OX40 (two immune check points) and PDL-1 and BCMA (an immune check point and a tumor marker of multiple myeloma).
On-going development of topical nano-formulated cyclosporine toward an investigational new drug application and initiation of 505(b) 2 clinical development.
"We are structuring the Company strategically to ensure long term comprehensive financing of our product pipeline and enable focused execution" said Dr. Daniel Teper, CEO of Immune Pharmaceuticals Inc. "We continue to progress in our clinical trials with bertilimumab as we increase patient enrollment and we are on track to achieve our operational and financial objectives for 2016."
First Quarter 2016 Financial Results
Immune reported a loss attributable to common stockholders of $6.0 million, or $0.17 per share, for the quarter ended March 31, 2016, compared to a loss attributable to common stockholders of $3.6 million, or $0.15 per share, for the quarter ended March 31, 2015.
R&D expenses increased by $0.9 million, due to higher salaries and employee benefits, license fees and clinical trial expenses. Salaries and employee benefits increased due to higher R&D employee head count for the three months ended March 31, 2016 compared with the three months ended March 31, 2015. G&A expenses increased by $0.1 million due to higher salaries and rent expense partially offset by lower professional fees.
Non-operating expense was $0.7 million during the three months ended March 31, 2016 compared with non-operating expense of $0.1 million during the three months ended March 31, 2015, an increase of $0.6 million which is primarily due to higher interest expense and derivative liability expense.
About Immune Pharmaceuticals Inc.:
Immune Pharmaceuticals Inc., (IMNP) together with its subsidiaries, is a clinical stage biopharmaceutical company specializing in the development and commercialization of novel targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company focuses on a precision medicine approach to treatment of diseases by incorporating methods for better patient selection in its clinical trials and the potential for development of companion diagnostics. The Company's immuno-inflammation product pipeline includes: bertilimumab, a clinical-stage first-in-class fully human antibody, targeting eotaxin-1, a key regulator of immuno-inflammation, a portfolio of clinical-stage immune oncology products and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. For more information, visit Immune's website at www.immunepharma.com, the content of which is not a part of this press release.
Forward-Looking Statements
This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal" or the negative of those words or other comparable words to be uncertain and forward-looking. Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include, but not limited to: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for bertilimumab or AmiKet will not be successful; the risk that bertilimumab, AmiKet or compounds arising from our NanomAbs program will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet on attractive terms, on a timely basis or at all; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q, and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings, which are available at www.sec.gov or at www.immunepharma.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties, or other risk factors. We expressly disclaim any obligation to publicly update any forward looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.
Jeffries states Buy (Raised to $5)
http://247wallst.com/investing/2016/05/06/top-analyst-upgrades-and-downgrades-activision-blizzard-berkshire-hathaway-fireeye-immunomedics-square-sunpower-weatherford-williams-and-yelp/
Immunomedics Inc. (NASDAQ: IMMU) was raised to Buy from Hold and the price target was raised handily to $5.00 from $1.50 at Jefferies. Wells Fargo maintained its Outperform rating with a valuation range of $3.00 to $3.50, noting that IMMU132 has emerged as a major value driver accelerating its approval potential. The stock closed down 7.5% at $3.46 on Thursday. Its 52-week range is $1.50 to $5.05.
Read more: Top Analyst Upgrades and Downgrades: Activision Blizzard, Berkshire Hathaway, FireEye, Immunomedics, Square, SunPower, Weatherford, Williams and Yelp - 24/7 Wall St. http://247wallst.com/investing/2016/05/06/top-analyst-upgrades-and-downgrades-activision-blizzard-berkshire-hathaway-fireeye-immunomedics-square-sunpower-weatherford-williams-and-yelp/#ixzz47skcCoUX
Follow us: @247wallst on Twitter | 247wallst on Facebook
ImmunoCellular Therapeutics Receives Regulatory Approval in Canada, the UK and the Netherlands to Initiate ICT-107 Phase 3 Trial in Newly Diagnosed Glioblastoma
https://finance.yahoo.com/news/immunocellular-therapeutics-receives-regulatory-approval-100000934.html
LOS ANGELES, May 6, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the Company has received approval from regulatory authorities in Canada, the United Kingdom and the Netherlands to initiate the ICT-107 Phase 3 registration trial in patients with newly diagnosed glioblastoma. Patient screening is anticipated to commence shortly and the first clinical supplies could be manufactured for qualifying patients in Canada and Europe in the third quarter of 2016. The Company also is near to completing interactions with regulatory authorities in six other European countries and currently expects approval of those clinical trial applications in June 2016, with patient screening to begin in the third quarter of 2016.
We are very pleased with the progress of our ICT-107 registrational trial in the US, Canada and Europe," said Andrew Gengos, ImmunoCellular Chief Executive Officer. "We recently held our European investigator kick off meeting in Barcelona and had 100% attendance of investigators and coordinators from the 48 European clinical sites planning to participate in the trial. We are deeply appreciative of the support and enthusiasm expressed by our European colleagues, and their recognition of the importance and potential promise of the ICT-107 program, in light of the high unmet need and lack of new treatments for patients with brain cancer. We think that the ICT-107 program could be the best designed registrational program underway in newly diagnosed glioblastoma and look forward to announcing the treatment of our first patient."
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The phase 3 registrational trial of lead product candidate, ICT-107, a patient-specific, dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells, is open for patient screening. ImmunoCellular's pipeline also includes: ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. To learn more about ImmunoCellular, please visit www.imuc.com.